New Data Highlights Positive Results Of Namenda(R) (Memantine HCl) Once-Daily Extended-Release Formulation

�Forest Laboratories, Inc. (NYSE: FRX) presented positive Phase III data of a once-daily extended-release formulation of Namenda� (memantine HCl) at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD). The survey evaluated the efficacy, safety and tolerability of an innovative, proprietorship, 28 mg once-daily extended-release formulation of Namenda compared to placebo in outpatients with